Objective-SGLT2 (sodium-glucose cotransporter 2) inhibition in humans leads to increased levels of LDL (low-density lipoprotein) cholesterol and decreased levels of plasma triglyceride. Recent studies, however, have shown this therapy to lower cardiovascular mortality. In this study, we aimed to determine how SGLT2 inhibition alters circulating lipoproteins. Approach and Results-We used a mouse model expressing human CETP (cholesteryl ester transfer protein) and human ApoB100
U nder normal physiological conditions, plasma glucose is filtered at the renal glomerulus and then fully reabsorbed in the proximal tubule. This process of reabsorption in the tubules is mediated by 2 glucose transporters: SGLT1 (sodium-glucose cotransporter 1), responsible for ≈10% of the reabsorption and SGLT2, responsible for ≈90% of the reabsorption. 1, 2 When circulating levels of plasma glucose exceed the renal threshold for glucose reabsorption (referred to as RT G ), glucose is excreted in the urine. In patients with type 2 diabetes mellitus, the RT G is increased, primarily because of an increase in SGLT2 expression, which contributes to maintenance of elevated blood glucose levels. [2] [3] [4] Drugs that inhibit SGLT transporters reduce plasma glucose levels. Phlorizin, which inhibits both SGLT1 and 2, produces glycosuria and normalizes circulating glucose levels in rodents. 5, 6 Within the past few years, several oral SGLT2 inhibitors (eg, canagliflozin, dapagliflozin, and empagliflozin) have been approved and widely used as treatments for type 2 diabetes mellitus. However, there have been some concerns as these drugs have consistently been found to increase LDL cholesterol (LDL-C) levels. Although the LDL-C increase is a concern, SGLT2 inhibitors are associated with reduced cardiovascular disease (CVD), including heart failure, and also vascular disease. 7, 8 Some drugs associated with increased LDL levels have been found to be either neutral or cardioprotective. Like SGLT2 inhibitors, fibric acids and fish oils reduce triglyceride levels and often raise LDL-C. This is in part because of reduced CETP (cholesteryl ester transfer protein) actions as its substrate VLDL is decreased. However, increased lipolysis of triglyceride, as occurs with fibrates 9,10 also increases VLDL to LDL conversion. Moreover, greater lipolysis also increases HDL-C (high-density lipoprotein cholesterol), which is seen in some but not all SGLT2 clinical trials. 11, 12 Many studies of SGLT2 inhibition in preclinical models such as mice and rats have been reported, but none of these studies explain the changes in circulating lipids that are seen in humans. Hence, an animal model with a lipoprotein profile similar to humans may be required to investigate the potential mechanism for SGLT2 inhibitor-induced lipid changes. To that end, transgenic mice overexpressing CETP and ApoB100 (apolipoprotein B100) were fed a high-fat diet (HFD), made diabetic through administration of a low dose of streptozotocin, and treated with either an SGLT2 antisense oligonucleotide (ASO) or canagliflozin to inhibit SGLT2. We then went on to define the changes in lipoprotein physiology that resulted from inhibition of SGLT2.
Materials and Methods
All data and supporting materials have been provided with the published article.
Ethical Statement for Animal Studies
All procedures were conducted in conformity with the National Institutes of Health's Public Health Service Policy on Humane Care and Use of Laboratory Animals and the National Research Council of the National Academy of Sciences' Guide for the Care and Use of Laboratory Animals and were approved by the New York University Langone Medical Center Institutional Animal Care and Use Committee.
Mice Strains, Housing, Husbandry, and Diets
Eight to 10-week-old male CETP-ApoB100 transgenic mice on a background of C57Bl/6 (3716-M) were purchased from Taconic Bioscience, Inc (Hudson, NY). After 1 week of acclimatization, the mice were fed a 60% HFD (Research Diets, D12492) till the end of the study (16 weeks). These mice were used for the results shown in Figures 1  through 6 and Figures I and II in the online-only Data Supplement. For the data presented in Table I in the online-only Data Supplement, 10 to 12-week-old male wild-type C57Bl/6J mice on laboratory chow diet were used. These mice were initially purchased from Jackson Laboratory (number 000664, Bar Harbor, ME) and then bred in the mice facility at the New York University Langone Medical Center.
Mice were maintained in a 12-hour light/dark cycle and given free access to food and water, except when blood samples were obtained. Mice were monitored regularly to ensure their welfare.
Induction of Diabetes Mellitus
CETP-ApoB100 transgenic mice were made diabetic by intraperitoneal administration of streptozotocin (S0130 from Sigma-Aldrich, St. Louis, MO) at 2 concentrations: day 1 at 50 mg/kg, day 2 to 7 at 25 mg/kg. 13 Blood glucose was measured from tail bleeding using a hand-held glucometer and glucose strips (OneTouch Ultra) and was monitored during the first week of streptozotocin administration, and then once a week throughout the treatment period. Wild-type C57Bl/6 mice were made diabetic by intraperitoneal injection of streptozotocin (dose of 50 mg/kg body weight) for 5 consecutive days. Fasting blood glucose were monitored during the streptozotocin-treatment period and then once a week throughout the 4-week treatment period. Animals that had fasting blood glucose concentrations higher than 250 mg/dL were considered as diabetic.
Study Design and Drug Treatments
A total of 40 diabetic CETP-ApoB100 transgenic mice were assigned to 1 of 4 treatment groups (n=10 per group). Mice in group 1 received vehicle (0.5% methocel solution) daily by oral gavage for 4 weeks. Mice in group 2 received canagliflozin daily by oral gavage at a dose of 30 mg/kg (a concentration of 6 mg/mL in 0.5% methocel solution) for 4 weeks. Canagliflozin and methocel were provided by Janssen Research & Development. Mice in group 3 were injected intraperitoneally with the SGLT2 ASO at a dose of 10 mg/kg body weight, once a week for 4 weeks. The SGLT2 ASO (Ionis 388625) provided by Ionis Pharmaceutical is a 12-mer phosphorothioate oligonucleotide gapmer containing 2′-0-(2-methoxyethyl)-modified ribonucleosides (2′-MOE) at the 2 flanking positions surrounding an 8 base gap containing 2′-deoxynucleosides (2-8-2 design with a sequence of 5-TGTTCCAGCCCA-3.
14 Mice in group 4 had insulin pellets (LinShin Canada Inc, Ontario, Canada) implanted subcutaneously to achieve a slow-release of insulin (0.1 U/d) over the treatment period. 15 During the 15th week of the study, 1 mouse in the canagliflozin group and 1 mouse in the insulin group were found dead, although there were no obvious changes in their appearance or behavior before that.
In another experiment (Table I in the online-only Data Supplement), a group of 10 wild-type C57Bl/6 male mice on chow diet was made diabetic. Another group of 10 wild-type C57Bl/6 male mice on chow diet was injected with vehicle only to serve as the nondiabetic control group. Next, the diabetic group and the nondiabetic group were further divided into 2 groups: one treated with control ASO (nontargeting) and the other treated with SGLT2 ASO (dose of 10 mg/kg body weight), once a week for 4 weeks. Nondiabetic mice with control ASO and SGLT2 ASO had 5 mice in each group. Out of 10 mice injected with streptozotocin, 2 did not develop hyperglycemia and were excluded from the study at that point. Hence, diabetic mice with control ASO and SGLT2 ASO had 4 mice in each group.
Blood Sampling
All the blood samples for measuring total cholesterol (TC), triglyceride, lipoprotein profiling, postheparin LpL (lipoprotein lipase) activity were collected after a 4-hour fasting period. Mice were anesthetized using isoflurane and blood was collected from the retro-orbital plexus into tubes containing EDTA. Blood was centrifuged at 10 000g for 10 minutes for collection of the plasma, which was then used immediately for analysis and the rest frozen at −80°C. Plasma insulin was quantified using Mouse Ultrasensitive Insulin ELISA kit (ALPCO, Salem, NH).
Tissue Collection
At the end of the study, mice (fasted for 4 hours) were anesthetized with xylazine (10 mg/kg) and ketamine (100 mg/kg) and then perfused by heart puncture with PBS till the livers were blanched. Tissues were rapidly excised and snap frozen in liquid nitrogen unless otherwise noted.
Lipid Extraction From Heart
The lipid extraction protocol was adapted from Folch et al. 16 Approximately 100 mg of frozen tissue was homogenized in 1 mL of PBS using stainless steel beads for 1 minute in a bead beater homogenizer. From each sample, 50 μL was removed for protein analysis and 3 mL of 2:1 chloroform: methanol was added to the remainder of the sample and vortexed. Samples were then centrifuged for 10 minutes at 3000 rpm at 4°C. The lower, organic phase was then collected and dried under nitrogen gas. The dried lipid was then dissolved in 500 μL of 1% Triton-X 100 in chloroform, further dried and then dissolved in 100 μL of double distilled water. This was then used for enzymatic detection of lipids or stored at −20°C.
Lipid Measurements
Triglyceride and TC were measured using Infinity Triglyceride Reagent and Infinity Total Cholesterol Reagent (Thermo Scientific, Waltham, MA). Lipoproteins-VLDL d<1.006 g/mL, LDL d 1.006 to 1.063 g/ mL, and HDL d 1.063 to 1.21 g/mL-were separated by sequential density ultracentrifugation of mouse plasma in a TLA 100 rotor (Beckmann Instruments, Palo Alto, CA). Nonesterified fatty acid (NEFA) levels were measured using a kit (Wako Diagnostics, Richmond, VA).
Western Blot Analysis
Snap-frozen liver samples were homogenized using a RIPA buffer with protease inhibitors. Protein concentrations were determined using Pierce BCA Protein kit (Thermo Scientific, Waltham, MA). Forty microgram samples of total protein were used for Western blot analysis with mouse LDLR (LDL receptor) antibody (R&D AF2255, Carlsbad, CA) at 1:1000 dilution. HSP90 antibody (Abcam ab87133, Cambridge, MA) was used for control of protein loading at a dilution of 1:1000.
Tissue Gene Expression
Total RNA was prepared using a GeneJET RNA Purification Kit (Thermo Scientific, Waltham, MA). One microgram of RNA was used for reverse transcription using the Verso cDNA synthesis kit (Thermo Scientific, Waltham, MA) or the High-Capacity cDNA Reverse Transcription Kit (Thermo Scientific, Waltham, MA). Realtime quantitative PCR was performed using an ABI 7700 (Applied Biosystems, Foster City, CA). Amplification was performed using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA). Primers used for PCR amplification were obtained from Primer Bank (http://pga.mgh.harvard.edu/primerbank/). Data were normalized with HPRT1 (hypoxanthine phosphoribosyltransferase 1) or RPS3 (ribosomal protein S3) genes.
Hepatic Triglyceride Secretion
To measure hepatic triglyceride production rate, mice were injected intraperitoneally with Poloxamer-407 (P-407), (Sigma-Aldrich, St. Louis, MO) at 1 g/kg (in saline) after a 4-hour fasting period. Immediately before injection, and at 1, 2, and 4 hours after injection, blood samples were drawn in heparinized capillary tubes, plasma was prepared, and triglyceride concentrations were determined.
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Olive Oil Gavage
After a 4-hour fast, mice were given olive oil by oral gavage at 10 mL/kg (≈300 μL). Blood samples were drawn at baseline, 1, 2, and 4 hours after receiving the olive oil gavage.
VLDL Turnover Assay
VLDL was isolated from human plasma by density gradient ultracentrifugation.
14C
Triolein (Perkin Elmer, MA) was dried down in a triolein/mL of VLDL was used for 20 mice. VLDL was then dialyzed in a buffer containing 150 mmol/L NaCl and 0.24 mmol/L EDTA at 4°C and counts were measured. Radiolabeled VLDL was then diluted with PBS and injected intravenously in mice (1×10 6 cpm/mouse). Blood samples were collected before (0) and 30 seconds, 5 minutes, 15 minutes, 30 minutes, and 60 minutes after injection. Plasma was separated and counts were measured using 10 μL plasma in a scintillation counter.
LDL Turnover Assay
LDL was isolated by density gradient ultracentrifugation of plasma from LDLR knockout mice on Western diet for 4 weeks. After dialysis to remove excess salt, ≈1 mL LDL was incubated with 300 µCi of [3H] cholesteryl oleate ester (dried down in a glass vial) and 1 mL of CETP-containing 1.21 bottom fraction. G418 antibiotic was added to prevent contamination. The glass vial was incubated overnight at 37°C with constant shaking by inversion. LDL was again isolated by density gradient centrifugation and dialyzed in a buffer containing 150 mmol/L NaCl and 0.24 mmol/L EDTA at 4°C and counts were measured. Radiolabeled LDL was then diluted with PBS and injected intravenously in mice (5×10 6 cpm/mouse). Blood samples were collected before (0) and 30 seconds, 5 minutes, 15 minutes, 30 minutes, 60 minutes, and 120 minutes after injection. Plasma was separated and counts were measured using 10 μL plasma in a scintillation counter.
VLDL and LDL were labeled separately as described above and were mixed together with PBS and injected intravenously in mice in a total volume of 100 μL.
LpL Activity Assay
Postheparin plasma LpL activity was determined as previously described. 18 Postheparin plasma was obtained from 4-hour fasted mice, 5 minutes after intravenous injection of 10 U of heparin. To measure total lipase activity, plasma was incubated with 10% Intralipid/ [3H] triolein (Perkin Elmer, MA) emulsion as substrate and heat-inactivated human serum as the source of apoCII. The contribution of HL (hepatic lipase) in the plasma was determined by including NaCl (final concentration 1 mol/L) in the assay and was subtracted from the total lipase activity to estimate specific LpL activity. Lipase activity was expressed as μmol FFA/mL per hour. Aliquots of human postheparin plasma were used for a standard curve in all the experiments.
Statistical Analyses
Data are presented as means±SD. Statistical differences were assessed via unpaired Student t test (for comparison among 2 groups) or a 1-way/2-way ANOVA (Dunnett test, Fisher LSD or Tukey test for post hoc analysis where appropriate) for comparison among multiple groups, using GraphPad Prism 7. A P value of <0.05 was considered as significant. Figure 1A shows the experimental design for this study. Forty CETP-ApoB100 transgenic mice were fed a 60% HFD for 11 weeks and then diabetes mellitus was induced with a low dose of streptozotocin. The mice developed hyperglycemia within a week ( Figure 1B ) and subsequently were divided into 4 groups: controls treated with vehicle (0.5% methocel), canagliflozin-treated, SGLT2 ASO-treated, and insulin-treated. All 3 interventions-canagliflozin, SGLT2 ASO, and insulinlowered blood glucose in the diabetic mice compared with vehicle; the mean glucose levels across the 4 groups at the end of the 4-week treatment period were 443 mg/dL in vehicle, 176 mg/dL with canagliflozin, 200 mg/dL with SGLT2 ASO, and 234 mg/dL with insulin ( Figure 1B ; P<0.05 versus vehicle). Body weight increased after HFD feeding, and the mice lost weight after streptozotocin treatments; however, there was no difference among the 4 treatment groups ( Figure 1C) . Insulin levels were low in the streptozotocin-treated mice, and canagliflozin further reduced the insulin level compared with vehicle ( Figure 1D) , similar to what is seen in humans treated with SGLT2 inhibitors. 19, 20 Both insulin and ASO reduced circulating NEFA ( Figure 1E ). SGLT2 gene expression in the kidney was suppressed >90% by SGLT2 ASO, whereas canagliflozin and insulin treatments slightly reduced SGLT2 mRNA ( Figure I in the online-only Data Supplement).
Results
SGLT2 Inhibition Lowers Blood Glucose in Diabetic CETP-ApoB100 Transgenic Mice
SGLT2 Inhibition Alters Plasma Lipids
Next, we measured plasma lipid levels in these diabetic CETPApoB100 mice, which have a plasma lipoprotein distribution similar to humans. After 4 weeks of intervention, both canagliflozin and SGLT2 ASO treatments raised plasma TC, from 165 mg/dL in vehicle to 183 mg/dL with canagliflozin and 200 mg/dL with SGLT2 ASO. Insulin treatment also raised TC modestly ( Figure 2A ). The increase in TC seen with SGLT2 inhibition was attributed to an increase in LDL-C; the LDL-C level was 71 mg/dL in vehicle, 89 mg/dL with canagliflozin (25% increase), and 108 mg/dL with SGLT2 ASO (52% increase; Figure 2B ). HDL-C levels did not change with the SGLT2 ASO or canagliflozin but increased with insulin treatment ( Figure 2C) .
In contrast to canagliflozin, which did not change plasma triglyceride, SGLT2 ASO, and insulin reduced circulating triglycerides ( Figure 2D ) because of a reduction in VLDL-triglyceride ( Figure 2E ). These lipid alterations of increased LDL-C and reduced triglycerides were similar to those found with SGLT2 inhibition in humans with diabetes mellitus, although in our studies the greatest changes were found with SGLT2 ASO. SGLT2 ASO treatment in diabetic or nondiabetic wild-type C57Bl/6 mice lacking CETP and ApoB100 transgenes had no effect on plasma LDL-C compared with control ASO-treated mice (Table I in the online-only Data Supplement). Our previous study with canagliflozin treatment also did not raise plasma LDL-C in diabetic or nondiabetic wild-type mice.
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SGLT2 Inhibition Increases Triglyceride Clearance
We next investigated the effect of SGLT2 inhibition on triglyceride metabolism and specifically assessed whether the reduction of plasma triglyceride in the ASO-treated mice was because of reduced hepatic triglyceride production or increased clearance from circulation. Subsets of the mice in all 4 groups were fasted for 4 hours and injected with P-407 to block lipolysis and to measure hepatic triglyceride secretion. During the 4-hour study, there was no significant difference in rates of triglyceride secretion among the groups ( Figure 3A) . Next, we analyzed postprandial lipemia, which is an index of blood triglyceride clearance and often viewed as an in vivo assay of lipolytic capacity. The mice were gavaged with olive oil, and plasma triglyceride was measured over time. SGLT2 ASOtreated but not canagliflozin-treated mice cleared the triglyceride faster than the vehicle-treated mice ( Figure 3B ). Insulin treatment also caused faster clearance of triglyceride from the circulation, as previously reported. 21 Additionally, we studied turnover of human VLDL in a separate group of diabetic CETPApoB10 mice. SGLT2 ASO-treated mice cleared VLDL tracer from the circulation faster than control ( Figure 3C ). To assess if faster triglyceride clearance correlated with increased triglyceride lipase activity, we measured total, HL (hepatic lipase), and LpL activities in the postheparin plasma from these mice. SGLT2 ASO, canagliflozin, and insulin treatments increased total triglyceride lipase activity, as well as LpL activity in the postheparin plasma. These increases were greater with SGLT2 ASO than with canagliflozin.
SGLT2 Inhibition Downregulates ANGPTL4 Expression in Adipose, Skeletal Muscle, and Heart
To determine the reason for the changes in LpL activity, we examined gene expression of LpL and its known inhibitor ANGPTL4 (angiopoietin-like protein 4) in white and brown adipose, skeletal muscle, and heart, the tissues with highest LpL expression. [22] [23] [24] LpL mRNA expression was unchanged in the 3 treatment groups in all these tissues ( Figure 4A through 4D) . Canagliflozin, as well as insulin, reduced ANGPTL4 expression in white adipose tissue, whereas SGLT2 ASO reduced its expression in brown adipose, skeletal muscle, and heart similar to insulin (Figure 4A through 4D) . Hepatic mRNA expression of HL and ANGPTL3, another posttranslational inhibitor of LpL, was not altered in any of the treatment groups ( Figure 4E ).
SGLT2 Inhibition Decreases LDL Turnover
The increased LDL-C in the mice might be because of greater LpL-mediated conversion of VLDL to LDL. However, it is also possible that our treatments altered clearance of LDL from the circulation. To test this, we assessed LDL turnover. SGLT2 ASO-treated mice had significantly delayed LDL turnover compared with the other groups ( Figure 5A ). Because hepatic LDLR is the major receptor for clearance of plasma LDL, we measured the gene expression of LDLR and its posttranscriptional modulator PCSK9 in the liver. SGLT2 ASO treatment lowered mRNA levels of both genes ( Figure 5B ). Total hepatic LDLR protein levels decreased modestly in SGLT2 ASO-treated mice ( Figure 5C and 5D ).
SGLT2 Inhibition Increases Cardiac NEFA Levels
Because SGLT2 inhibition treatments are also associated with reduced heart failure, we analyzed cardiac lipid levels and major genes involved in lipid metabolism. Cardiac NEFAs were increased with SGLT2 inhibition ( Figure 6A ). Heart triglyceride content increased with canagliflozin only (Figure 6B ), whereas TC levels in the heart were not altered by any of the treatments ( Figure 6C) . We assessed the expression of PPARs (peroxisomal proliferator-activated receptors). Canagliflozin treatment lowered PPAR-α gene expression; however, SGLT2 ASO did not alter mRNA expression of cardiac PPAR genes ( Figure 6D ). In the heart, PPAR-δ is the major regulator of ANGPTL4 expression 22, 25, 26 ; however, none of the treatments altered PPAR-δ mRNA levels. Gene expression of FoxO1 (Forkhead box protein O1), another ANGPTL4 regulator, 27 was not altered with SGLT2 inhibition as well ( Figure 6D ). CPT1b (carnitine palmitoyltransferase 1B), which is involved in fatty acid oxidation, was downregulated along with ACSL1 (Acyl-CoA synthetase long chain family member 1), VLDLR, and CD36 in insulin and ASO-treated mouse hearts ( Figure 6E ). Gene expression of BNP (B-type natriuretic peptide), a heart failure marker was lower in SGLT2 ASO-treated mice hearts, whereas expression 
Discussion
SGLT2 inhibitors are rapidly becoming a preferred drug for patients with type 2 diabetes mellitus as they reduce glucose, cause weight loss, and offer protection from cardiovascular complications, especially heart failure, as recently demonstrated in the EMPA-REG (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) and CANVAS (Canagliflozin Cardiovascular Assessment Study) trials. 7, 8 This cardiovascular benefit occurs despite an increase in LDL-C found in several clinical studies. 11, 12 However, like some other triglyceride-reducing therapies, the changes in LDL-C occur in the setting of other beneficial changes in plasma lipoprotein metabolism.
For our study, we chose a mouse model of combined insulin resistance and insulin deficiency seen in patients with type 2 diabetes mellitus. Mice were first made obese on an HFD and then insulin deficient using streptozotocin, albeit at lower doses than used in chow-fed animals, leading to hyperglycemia in concert with insulin resistance. We used mice that contained 2 transgenes, human ApoB100 to increase circulating VLDL and LDL, and human CETP to allow exchange of lipids between HDL and ApoB-containing lipoproteins. In contrast to the several previous studies where SGLT2 inhibition by drugs or ASO did not increase plasma LDL-C, 13, [28] [29] [30] [31] [32] [33] SGLT2 inhibition using our novel diabetic animal model reproduced many of the lipid alterations found in humans treated with SGLT2 inhibitors, namely increased LDL-C and reduced triglyceride. Similar changes in triglyceride were found with insulin treatment, which is not surprising as others have shown that one effect of SGLT2 inhibition treatment is improved insulin actions. 20 Unlike the weight loss is seen in patients treated with SGLT2 inhibitors, we did not observe such weight reductions in our model with either ASO or canagliflozin. The general weight loss seen in all 4 groups of mice treated with streptozotocin mice may have preempted any further effect of SGLT2 inhibition on body weight.
In this study, we were able to examine the reasons for changes in lipoprotein physiology that accompany SGLT2 inhibition. SGLT2 ASO and canagliflozin treatment in mice also increased total postheparin plasma lipolytic activity and LpL activity. With greater LpL activity, triglyceride was reduced and postprandial lipemia blunted in SGLT2 ASO-treated mice. Likely because of the less robust induction of LpL, these changes were not evident in canagliflozin-treated mice. Both postprandial triglyceride Effect of SGLT2 (sodium-glucose cotransporter 2) inhibition on hepatic VLDL (very-low-density lipoprotein) production, postprandial lipemia, and VLDL turnover. A, Hepatic VLDL production was determined in 4-h fasted mice after injection with P-407 to inhibit lipolysis. Blood samples were collected at 0, 1, 2, and 4 h after P-407 and processed to measure plasma triglyceride (TG) accumulation (n=4-5 per group). B, Postprandial triglyceride (TG) clearance after oral gavage of olive oil (≈300 mL). TG levels were measured 0, 1, 2, and 4 h after gavage (n=4-5 per group); (C) VLDL turnover after intravenous injection of [C14] triolein-labeled human VLDL over time in CETP (cholesteryl ester transfer protein)-ApoB100 (apolipoprotein B100) mice treated with vehicle, canagliflozin, control antisense oligonucleotides (ASO) or SGLT2 ASO (n=4-5 per group). D, Total TG lipase, HL (hepatic lipase), and LpL (lipoprotein lipase) activities in postheparin plasma from the 4 mice groups using a radiolabeled TG substrate as described in Methods (n=4-5 per group). Values represent mean±SD. *P<0.05 and **P<0.01 when Student t test was used for analysis; #P<0.05, ##P<0.01, and ###P<0.001 when ANOVA was used for analysis. All comparisons are with control vehicle group.
and VLDL-triglyceride turnover were increased in ASO-treated mice, consistent with the increased LpL activity.
The increased LpL activity was not accompanied by a corresponding change in LpL mRNA, suggesting that a posttranscriptional mechanism was operative. Specifically, we found that gene expression of ANGPTL4, which inactivates LpL activity by increasing dissociation of LpL dimers, 24 was markedly reduced in heart, skeletal muscle, and brown adipose tissue with SGLT2 ASO treatment. ANGPTL4 is mainly regulated by PPARs, 25, 26, 34, 35 which are in turn activated by fatty acids. Canagliflozin did not alter plasma NEFA levels, but SGLT2 ASO lowered them. This could explain reduced ANGPTL4 expression in metabolic tissues with ASO treatment. Future studies are warranted to define the detailed mechanisms.
To our surprise, the mice treated with SGLT2 ASO had more pronounced lipid changes than mice treated with canagliflozin despite similar changes in fasting glucose. This could be because of the differences in the duration of pharmacodynamic effects of SGLT2 ASO versus canagliflozin. The estimated half-life of ASO in the kidney is expected to be at least 2 to 4 weeks. However, it is possible that canagliflozin's shorter half-life, effects of the daily oral gavage (eg, stress), or a reduced or less prolonged effect on nonrenal SGLT2 transporter mitigated some of the effects compared with the ASO. Hence, we have focused on the effects of SGLT2 ASO in this report.
The increase in plasma LDL-C found in our study could be because of increased VLDL to LDL conversion as well as reduced LDL clearance. Because of the rapid clearance of VLDL in the mouse, we were unable to track conversion but did find a reduced LDL-C turnover. LDLR mRNA was reduced in the ASO-treated mice; LDLR protein was modestly reduced. The only other animal study showing elevated plasma LDL-C with SGLT2 inhibition was performed in nondiabetic HFD-fed hamsters. 33 The hamsters treated with empagliflozin had increased hepatic cholesterol synthesis as well as reduced LDL clearance associated with reduced LDLR levels. However, the animals were not diabetic, and changes in plasma lipids were seen only after overnight fasting, which is different than our study, where we saw lipid changes after a more physiological 4-hour fast. Changes in circulating triglyceride were not reported for the hamsters. Other treatments that increase LpL activity or reduce triglyceride, such as fibric acids and omega-3 fatty acids, also increase LDL-C levels. 36, 37 In some situations, these LDL-C increases accompany reduced triglyceride levels and likely reduce the CETP-mediated transfer of LDL-C to VLDL. Reduced VLDL-triglyceride and increased LpL activity also likely explains the HDL increase seen in humans treated with SGLT2 inhibitors. Increased LpL reduces postprandial lipemia, a well-established risk factor for CVD. 38, 39 Further support of the role of lipolysis in CVD risk has come from Genome-Wide Association Study and large-scale exome wide screening studies that have linked loci associating with triglyceride levels and CVD. Changes in LpL correlate with CVD risk. 40 Although the reason for the marked reduction in heart failure seen in the EMPA-REG and CANVAS trials are unclear, hypotheses include an effect because of reduced blood pressure, vascular dilation, increased use of ketone bodies as a cardiac fuel source, 41 and reduced substrate overload because of lower circulating glucose without greater insulin-driven nutrient uptake. 42 One characteristic of many forms of heart failure is a deficiency in energy production. 43 The major substrate for heart ATP production is fatty acid, and heart failure is usually associated with reduced fatty acid oxidation. 44, 45 Although it has been argued that reduced fatty acid oxidation could be beneficial as oxidation of glucose requires less oxygen than that of fatty acids, 46 it is also possible that this metabolic switch exacerbates energy deficiency. If true, then the reduction of ANGPTL4 found in our studies would likely lead to increased LpL actions in the heart, and thus greater fatty acid uptake. This could explain the increase in cardiac fatty acid levels seen in our studies with SGLT2 inhibition. Others have shown that ANGPTL4 overexpression in cardiomyocytes leads to reduced LpL activity and small hearts that are prone to failure 23 ; cardiac LpL deficiency shows a similar increase in afterload-induced heart failure. 47 We postulate that reduced heart expression of ANGPTL4 improves heart energy production, which in turn will improve heart function.
In summary, we have defined the cause of increased LDL-C with the use of SGLT2 inhibition therapies. Our study demonstrated that LDL-C increases were associated with delayed clearance of LDL from the circulation along with increased plasma LpL activity, reduced postprandial lipemia, and lower circulating triglyceride levels in mice treated with the SGLT2 ASO. The major molecular change was a marked reduction in ANGPTL4 mRNA in heart, adipose, and skeletal muscle allowing greater LpL activity. Genetic studies have associated reduced ANGPTL4 with reduced CVD, 48, 49 suggesting that the clinical benefits of SGLT2 inhibitors on CVD might be via a similar mechanism.
